Physician profile
Dayna Garrison
NPI 1679273015
$3,195.08
in general payments reported to CMS, 2019-2025
19 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $746 · 2024: $1,409 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.70 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $834.40 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $825.05 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.22 | 2023-2025 | Ofev, Jardiance, Spiriva Respimat |
| Insmed, INC. | $230.52 | 2024-2025 | Arikayce |
| Amgen INC. | $145.86 | 2024 | Tezspire |
| Baxter Healthcare | $127.45 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $96.97 | 2023-2024 | Yupelri |
| United Therapeutics Corporation | $91.30 | 2024-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $59.65 | 2023-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $48.09 | 2023 | Glassia |
| Lilly USA, LLC | $30.38 | 2025 | Zepbound |
| Shionogi INC | $30.12 | 2024 | Fetroja |
| Merck Sharp & Dohme LLC | $28.70 | 2024 | Recarbrio, Zerbaxa |
| Janssen Pharmaceuticals, INC | $28.36 | 2024 | Xarelto |
| Phadia US INC. | $24.73 | 2024 | Immunocap |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $22.73 | 2025 | Opsynvi, Uptravi |
| Vifor Pharma, INC. | $20.17 | 2024 | Zemaira |
| Electromed, INC. | $16.38 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayna Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.